NPIL Pharma Agrees to Acquire Pfizer's Morpeth Manufacturing Facility, Signs Supply Agreement
NPIL Pharma, a subsidiary of Nicholas Piramal India Limited (Mumbai, India) has agreed to acquire the Morpeth, Northumberland, UK, manufacturing facility of Pfizer Inc. (New York, NY).
NPIL Pharma, a subsidiary of Nicholas Piramal India Limited (Mumbai,India, www.nicholaspiramal.com)has agreed to acquire the Morpeth, Northumberland, UK, manufacturingfacility of Pfizer Inc. (New York, NY, www.pfizer.com). The integrated site hasproduction and supply-chain capabilities that cover activepharmaceutical ingredients, finished dosage, packaging, anddistribution.
NPIL Pharma expects to complete the deal by June 19. In acquiring thefacility, NPIL Pharma also has entered into a supply agreement, worthup to $350 million, with Pfizer through November 2011.
The deal expands NPIL Pharma's sourcing relationship with Pfizer. NPILalready has a seven-year agreement, signed in December 2005, to provideprocess development and scale-up services to Pfizer's animal healthdivision.
The Morpeth acquisition is NPIL's third in the United Kingdom,following its purchase of Rhodia's (Paris, France, www.rhodia.com)inhalation anesthetics business in December 2004 and Avecia's custommanufacturing business in December 2005.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
